We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Levetiracetam in Neonatal Seizures as First-line Treatment: A Prospective Study.
- Authors
Falsaperla, Raffaele; Vitaliti, Giovanna; Mauceri, Laura; Romano, Catia; Pavone, Piero; Motamed-Gorji, Nazgol; Matin, Nassim; Lubrano, Riccardo; Corsello, Giovanni
- Abstract
Aim of the Study: The aim of this study is to evaluate the efficacy and safety of levetiracetam (LEV) as first‑line treatment of neonatal seizures. Materials and Methods: This study was conducted in patients of Neonatal Intensive Care Unit of Santo Bambino Hospital, University of Catania, Italy, from January to August 2016. A total of 16 neonates with convulsions not associated with major syndromes, which required anticonvulsant therapy, were included and underwent IV LEV at standard doses. Results: All patients responded to treatment, with a variety range of seizure resolution period (from 24 h to 15 days; mean hours: 96 ± 110.95). No patient required a second anticonvulsant therapy. Regarding safety of LEV, no major side‑effects were observed. Conclusions: To our knowledge, it is one of the few studies confirming the efficiency of LEV as first‑line treatment in seizures of this age group. LEV was effective in resolving seizures and was safely administered in the current study.
- Subjects
ITALY; DRUG therapy for convulsions; ANTICONVULSANTS; INTRAVENOUS therapy; LONGITUDINAL method; NEONATAL intensive care; SPASMS; NEONATAL intensive care units; TREATMENT effectiveness; TREATMENT duration; CHILDREN
- Publication
Journal of Pediatric Neurosciences, 2017, Vol 12, Issue 1, p24
- ISSN
1817-1745
- Publication type
Article
- DOI
10.4103/jpn.JPN_172_16